Abstract A new class of basic indirect pharmacodynamic models for agents that alter the loss of natural cells based on a lifespan concept are presented. The lifespan indirect response (LIDR) models assume that cells (R) are produced at a constant rate (k in ), survive during a certain duration T R , and finally are lost. The rate of cell loss is equal to the production rate but is delayed by T R . A therapeutic agent can increase or decrease the baseline cell lifespan to a new cell lifespan, T D , by temporally changing the proportion of cells belonging to the two modes of the lifespan distribution. Therefore, the change of lifespan at time t is described according to the Hill function, H (C(t)), with capacity (E max ) and sensitivity (EC 50 ), and the pharmacokinetic function C(t). A one-compartment cell model was examined through simulations to describe the role of pharmacokinetics, pharmacodynamics and cell properties for the cases where the drug increases
Introduction
Many pharmacological agents exhibit an indirect mechanism of action by inhibiting or stimulating production or loss of a biological signal or a biomarker that ultimately controls a therapeutically relevant response. Four basic pharmacodynamic (PD) models have been introduced that combined the turnover of the response variable with an indirect drug effect [1] . Since then, these types of models have been extensively studied and extended to account for complexities of biological systems such as multiple compartments, tolerance effects, feedback mechanisms and others [2] . Lifespan-based indirect response (LIDR) models have been proposed to describe drug effects on such systems like cell populations where the loss rate is more likely to be controlled by the natural cell senescence or its conversion to another cell type rather than by the size of the cell population [3] . However, the drug effects implemented in the LIDR models are limited to the inhibition or stimulation of the production rate of the response [3] , which makes them similar to the basic indirect response Models I and III [1] . A description of drug effects on the loss rate of the response, equivalent to the basic indirect response Models II and IV, requires the implementation of a mechanism that affects the distribution of lifespans in a drug concentration-dependent manner. Contrary to the basic indirect response models, such a process introduces a great deal of mathematical complexities to the pharmacodynamic models. However, models dealing with drug effects that alter the lifespan distribution of cell populations are of great interest to analyze the changes in cell lifespan due to the entry of younger cells in the circulation, the inhibition or stimulation of the apoptosis, and the modification of mature cell survival.
Among others, the hematopoietic cell populations are natural examples of biological systems governed by lifespan-based processes of cell proliferation, differentiation, maturation, and senescence [3] . Endogenous hematopoietic growth factors like erythropoietin (EPO), thrombopoietin, and granulocyte colony stimulating factor (G-CSF) and their therapeutic protein analogs fall into the category of agents that regulate not only the production of cells in the bone marrow and in blood, but also the apoptosis and cell survival. Consequently, their pharmacological effects could be adequately described by the LIDR models [4] [5] [6] . The major mechanism of action for erythropoietin is the receptor-mediated activation of the Janus kinase 2 signaling pathway that results in stimulation of proliferation of progenitors cells in bone marrow and inhibition of apoptosis [7] . Erythropoietin has been reported also to act as a survival factor [8] . The hypothesised role of EPO in neocytolysis also suggests that this cytokine exhibits a mechanism of action that affects the lifespan distribution of reticulocytes and red blood cells (RBC) [9] . Pharmacodynamic models of recombinant human erythropoietin (rHuEPO) effects on reticulocyte age markers have been developed recently [10] . The relationship between reticulocyte and RBC counts in healthy subjects receiving a single dose of rHuEPO indicated a dose dependent effect on the mean reticulocyte lifespan [11] . Therefore, we use rHuEPO and reticulocytes as an example of a system where a therapeutic agent affects the lifespan distribution of a clinically relevant biomarker. Other hematopietic growth factors have also been reported to affect lifespan distributions of blood cells. The effect of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) on the mean platelet lifespan has been investigated [12] . Administration of PEG-rHuMGDF to normal subjects prolonged the mean platelet lifespan from the baseline 8.5 days to 9.4 days on day 8 of the study. This effect was attributed to an increased number of young circulating platelets due to a prior stimulation of the production of bone marrow precursor cells. Similarly, Roskos et al. evidenced that pegfilgrastim stimulates early release of younger neutrophils from bone marrow in peripheral blood [13] .
The objective of this work is to introduce and systematically evaluate the basic indirect pharmacodynamic models for agents that alter the loss of natural cells based on the modification of cell lifespan distribution. The general theory is presented first and subsequently limited to a very simplistic distribution of cell lifespans. The onecompartment cell model is examined through a simulation exercise to describe the role of pharmacokinetics, pharmacodynamics and cell properties for the cases where the drug increases or decreases the cell lifespan. The differential equations, the explicit solutions of LIDR models for large doses and the area under the effect curve (AUCE) are derived. A pharmacokinetic and pharmacodynamic model of rHuEPO effect on reticulocyte accounting for both stimulation of the proliferation of bone marrow progenitor cells and increase of reticulocyte lifespans was applied to describe mean data from healthy subjects who received a single subcutaneous doses of rHuEPO ranging from 20 to 160 kIU.
Theoretical
The number of cells R in a population is controlled by two processes: cell production and cell loss. The net change in the cell number is determined by the difference between the production rate k in (t) and the elimination rate k out (t):
The fundamental assumption is that every cell in the population at any moment of time t is assigned to have a specific lifespan. The loss process is assumed to be a consequence of natural senescence or conversion to another cell type. Each cell lives for the same period of time and then disappears, therefore, the cells of the same age will leave the population at the same time. In general, the lifespans of cells can be time dependent. Then, the distribution of the cell lifespan is described by the following probability density function (p.d.f.) (t, τ ):
(t, τ ) τ = # cells with a specific lifespan at time t between τ and τ + τ (2)
The loss of cells from the population is totally determined by their lifespan distribution, then the elimination rate must satisfy the following relationship:
The derivation of Eq. 3 has been presented previously elsewhere [14] . In other words, the elimination rate for a cell population with a known lifespan distribution is equal to the convolution integral of the cell production rate and the p.d.f. for the lifespan distribution as shown in Eq. 4:
where the convolution operator '*' is defined by Eq. 3. In the simplest case of the point lifespan distribution δ(τ − T R ), where T R is the lifespan common for all cells:
Previously, it has been shown that the baseline cell count corresponding to the timeinvariant lifespan distribution 0 (τ ) is equal to the product of the baseline production rate k in0 and the mean lifespan T R [11] :
If C(t) denotes the drug plasma concentration that affects the cell lifespan distribution, then in the simplest case of the point distribution δ(τ − T R ), the most natural way of describing this drug effect would be via temporal changes of the value of T R :
where H (t) is a function that relates C(t) to the effect (e.g. the Hill function). This approach leads to difficult mathematical problems in calculation of the convolution integral Eq. 3 that have been solved by Freise et al. [15] . An alternative approach is presented here for lifespan distributions that are combinations of a finite number of the Dirac delta functions:
where
The time dependent coefficients can be considered as weights determining the contribution of each point distribution to the overall distribution. Our basic postulate is that the drug does not affect the location of points T 1 , . . . , T M on the lifespan axis, but rather impacts the weights α 1 (t), . . . , α M (t), and consequently temporally changes the lifespan distribution. Following the formalism of Eq. 7, the drug effect on the lifespan distribution can be described as
Contrary to Eq. 7, the convolution integral Eq. 3 can be easily calculated for the lifespan distribution described by Eq. 10 yielding
Notice that if M = 1, then according to Eq. 9, α 1 (t) ≡ 1 is a constant function and no drug effect can be exercised. Further, we consider the simplest non-trivial lifespan distribution that, in the absence of drug, is centered about T R . The drug effect is manifested by changing the weights between two point distributions δ(τ − T R ) and δ(τ − T D ), where T D is the lifespan of a cell exposed to the drug that can be longer or shorter than the lifespan of a cell in the absence of drug. The Hill function is used to describe the effect as shown in Eq. 12:
In the absence of drug (C(t) = 0), the p.d.f. in Eq. 12 reduces to δ(τ − T R ). According to Eqs. 1 and 11, the equations describing cell counts in the population with a constant production rate k in (t) ≡ k in is as follows
Equation 13 can be further simplified to
with the baseline condition
A schematic diagram for the LIDR model described by Eq. 14 is shown in Fig. 1 . Equation 12 allows one to determine the effect of drug on the mean lifespan according to Eq. 16.
Since the drug effect increases the contribution of δ(τ − T D ) into the cell lifespan distribution, if T D > T R , then the drug effect transiently increases the cell mean lifespan, whereas, if T D < T R , the mean lifespan transiently decreases and returns to T R after C(t) becomes 0. The increase in the mean lifespan results in accumulation of cells in the population followed by a return to the baseline number of cells and hence to the baseline mean lifespan. Such a time course is characteristic for the indirect response Model II where drug inhibits response removal [1] . Similarly, the transient decrease in the mean lifespan accelerates depletion of cells and a decrease in the cell count can be observed followed by its return to the baseline. This is a characteristic pattern for the indirect response Model IV where drug stimulated the response removal [1] . In that respect, the case T D > T R is analogous to IDR Model II, and the case T D < T R to IDR Model IV. These and other important properties of the R vs. t curve can be deduced from the following relationship derived in Appendix A:
Methods

Model exploration
The one-compartment cell model (Fig. 1 , Eq.14) was examined through a simulation exercise to describe the role of pharmacokinetics, pharmacodynamics and cell properties. Computer simulations of the basic LIDR were conducted using the ADAPT II software [16] . The effect of increasing doses was assessed through simulations of two distinct cases. In the first case, the drug effect increases the lifespan of exposed
In the second case, the drug effect decreased the lifespan of exposed cells from T R to T D (T D < T R ). Escalating doses ranging from 100 to 100,000 units were modelled as IV bolus inputs into the central compartment.
The monoexponential kinetics was assumed to follow Eq. 18:
where 
For each scenario, the production rate constant was calculated from the baseline Eq. 15. Calculus (limits, derivatives, and integration) was employed to explore the behavior of the pharmacodynamic response R as a function of time and dose. The characteristic points of the R vs. t curve such as the response peak (R peak ), time to response peak (T peak ), lag time (T lag ), and the area between the baseline and the response curve (AUCE) were calculated from Eq. 17 as integrals of the drug effect Hill function. Additionally, the limiting values of R(t) for large doses (D/V /EC 50 → ∞) were obtained.
Although all PD model parameters are identifiable, concerns can be raised about precision of parameter estimates if data is limited and exposed to noise due to assay or intra-individual variability. Estimability of the PD model parameters were studied by generating responses for the basic LIDR model with T D > T R at specified times 0, 24, 48, 60, 72, 96, 120, and 144 h for 100 subjects with the following residual error model (19) where t i denote the simulated times, and ε i are random variables ε i ∼ N(0, 0.1). The basic PK/PD parameter values were used with Dose = 100 mg and E max = 0.8. The individual responses were simulated by NONMEM V level 1.1 software package (GloboMax, Hanover, MD, USA). Subsequently, all individual responses were fitted by the same model and individual parameter estimates recorded and presented in the form of histograms. The estimates obtained after successful minimization were used for further analysis. The quartiles of the parameter estimate distributions were used as measures of the bias and precision of estimation.
Model application
Previously published data were used to illustrate the implementation and the application of the basic LIDR model with T D > T R into a more complex pharmacokinetic and pharmacodynamic (PK/PD) model of rHuEPO effect on reticulocytes accounting for both stimulation of the proliferation of bone marrow progenitor cells and increase of reticulocyte lifespans [11] . In this study, 48 healthy subjects were randomized to receive rHuEPO subcutaneously at doses of 20, 40, 60, 90, 120 and 160 kIU. All subjects received daily oral iron supplementation through day 29 of the study. Blood samples were collected 30, 20, and 10 min before drug administration and at 0.5, 1, 2, 5, 8, 12, 18, 24, 30, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216 , 264, 312 and 360 h after drug administration. Reticulocyte counts were measured before drug administration, daily up to 9 days, and then every other day up to 25 days and further at 28, 34 and 43 days after drug administration. The mean PK and PD data were used to quantify the effect of rHuEPO on reticulocyte survival. An average time a reticulocyte spends in the circulation prior to maturation to an erythrocyte is about one day [17] . Administration of a single dose of rHuEPO to healthy volunteers has been reported to temporally increase reticulocyte count [18] . Additionally, a transient increase in the reticulocyte residence time has been reported [10] . The rHuEPO effect has been attributed to release of immature reticulocytes from the bone marrow that need to spend more time in the circulation before they convert to mature RBC [19] . This phenomenon can be interpreted as a transient increase in the mean lifespan of the circulating reticulocytes [11] .
A previously published PK model has been applied to describe the time course of rHuEPO after subcutaneous administration [4] . The model structure used to characterize the rHuEPO disposition is displayed in Fig. 2 . Briefly, it is an open one-compartment model with non-linear elimination. Subcutaneous absorption of rHuEPO was described by a dual absorption model with a faster absorption process characterized by a zero-order input, and a parallel slower absorption process that started after the zero-order input ended, and was characterized by a first-order input into the central compartment. The model after subcutaneous administration can be described by the following system of differential equations:
with the initial conditions
where A SC and A E is the amount of erythropoietin in the subcutaneous and central compartments, k a is the absorption rate constant, F is the bioavailability, Fr denotes the fraction of a dose that is absorbed via a first-order process, whereas 1-Fr is absorbed at the zero-order rate during the time t lag . The endogenous EPO production rate constant k E P O forms another input to the central compartment. EPO is eliminated via a saturable process described by the Michaelis-Menten equation with parameters V max and K m , and V d denotes the volume of distribution. The step function θ(z) = 1 for z > 0 and θ(z) = 0 for z ≤ 0, and C 0 is the endogenous EPO concentration. The rHuEPO serum concentration was expressed by the ratio:
Since C 0 was selected as a model parameter, the endogenous EPO production rate was calculated from the steady-state equation for the compartment A E :
A previously published PD model was modified to describe the reticulocyte responses to rHuEPO treatment [5] . It is assumed that the progenitor cells BFU-E (BFU) are generated at a constant rate of k in and the differentiation of BFU-E cells into CFU-E (CFU) is controlled by a first-order process, k p , and stimulated by rHuEPO according to the Hill function
where C is serum rHuEPO concentration given by Eq. 23, S max is the maximum stimulation of BFU-E to differentiate to CFU-E, and SC 50 is the EPO concentration eliciting 50% of S max . Consequently,
The CFU-E cells proliferate on average M C FU times and transform to normoblasts (NOR) after their mean lifespan T C FU . Hence, the differential equation representing the change of CFU-E vs. time can be described as follows:
It is further assumed that normoblasts (NOR) proliferate M N O R times and are transformed to reticulocytes (RET) after their maturation time T N O R . Therefore, the differential equation representing the change of NOR vs. time can be described as follows
The production rate for RET is equal to the elimination rate for NOR. However, an additional effect of rHuEPO on the distribution of the RET lifespan was postulated. We assumed that rHuEPO transiently increases the baseline reticulocyte residence time in the circulation T R ET to T D according to Eq. 12 where the E max function was corrected for the presence of the endogenous EPO. Consequently, employing Eq. 11 to calculate the elimination rate for RET results in the following equation that is analogous to Eq. 13:
where,
and the E max value was fixed at 1, to reduce the number of model parameters. The initial conditions were obtained from the baseline (steady-state) equations as follows:
The BFU-E production rate constant was calculated as a secondary parameter according to Eq. 35.
The number of mitoses M C FU and M N O R were fixed at 4. The parameters k p and S max are not independently identifiable, therefore, the product k p · S max was directly estimated from the data. Also, since only the BFU variable is present in the equation describing RET, Eqs. 27 and 28 are not necessary to determine RET. Equation 16 describing the mean reticulocyte lifespan becomes Eq. 36.
M L R ET
During the estimation process, the measured rHuEPO serum concentrations and model predictions were transformed into logarithms. The magnitude of residual variability in the transformed serum concentrations was modelled using an additive error model. The residual variability in the reticulocyte counts was described by a combination of the additive and constant coefficient of variation models according to the equation:
where R obs was the observed reticulocyte count and ε 1 and ε 2 were independent, normally distributed random variables with zero means and variances σ 2 1 and σ 2 2 . Nonlinear regression fittings were performed using the NONMEM V level 1.1 software package (GloboMax, Hanover, MD, USA) including NM-TRAN (version III level 1.0) and PREDPP (version IV level 1.0). NONMEM was run under the Microsoft Windows operating system and compiled with Intel Fortran 9.0 for Windows. The implementation of the cell lifespan concept in NONMEM was done as previously described [20] .
Results
Model exploration
The purpose of the sensitivity analysis was to determine which part of the response vs. time curve is most sensitive to the perturbation of a model parameter and to interpret the dynamics of the system described by qualitatively analyzing the simulated profiles. In addition, this analysis helped to understand how and to what extent certain parameters control the behavior of the response described by the model.
The effect of dose on the response-time course is presented in Fig. 3 using the basic PK/PD parameters. If T D > T R , the response remains for all doses at the baseline level up to T R and starts to increase to reach the peak value at time T D , followed by a gradual return to the baseline. Both the peak response and the time needed for the response to return to baseline increases with increasing doses (Fig. 3, middle pannel) . Similarly, if T D < T R , the response remains at the baseline level up to T D for all doses and starts to decrease to reach the peak value at time T R , followed by a gradual return to the baseline. The peak decreases and the time for the response to return to the baseline increases with increased doses. In each case, the time to reach the peak response was dose independent and equivalent to T D + T R . Similarly, both the peak and the initial slope approached limiting values with large doses. The sharpness of the peaks was highest for the doses in the range 10 3 -10 4 units and decreased for smaller and larger doses.
The changes in the response vs. time profiles-corresponding to 0.2 increments in the E max values are shown in Fig. 4 (upper panels) . Relative to the baseline, the response increases (T D > T R ) or decreases (T D < T R ) proportionally to E max values. Consequently, E max acts as a scaling factor for the difference R max − R 0 . As expected for basic LIDR, the time to peak response did not depend on E max . The lower panels of Fig. 4 show the effect of EC 50 on the response vs. time profiles. They are identical to the plots presented in Fig. 3 , except that they appear in inverse order with respect to the EC 50 values. This is expected for monoexponential kinetics where both Dose and EC 50 appear in the Hill function only as the combination Dose/V /EC 50 . Therefore, an increase in the EC 50 value causes the same effect on the response curve as a proportional decrease in Dose and vice versa.
The effects of T D on the R vs. t curve are presented in Fig. 5 (upper pannel). Since for T D > T R , T D is equal to the time to peak response, an increase in T D value results in a shift of the time to peak response to the right with a corresponding increase in the peak response value. The sharpness of the peak decreases with increased T D . Since for T D < T R , T D is equal to the lag time, a decrease in T D value results in a decrease of the lag time with a corresponding decrease in the peak value of the response variable. Since the time to peak response remains at T R , the sharpness of the peak increases with decreased T D . The lower panels of Fig. 5 show the effect of a change in the baseline R 0 on the R vs. t curves. For both models, R 0 acts as a scaling factor where an increase in the R 0 value causes a proportional increase in the R values. Figure 6 represents the effects of T R on the R vs. t curve. Since T R occurs in the baseline Eq. 15, two sets of simulations were performed. The first assumed that k in was calculated according to Eq. 15, which resulted in a baseline that is independent of T R . The second was free of this constraint (Fig. 6, lower to the lag time, a decrease in T D value results in a decrease of the lag time in the response curve with a corresponding increase in the peak value of the response variable for simulations under the constraint and a decrease for simulations without the constraint. The time to peak remains at T D and the sharpness of the peak increases with decreased T R . Since for T D < T R , T R is equal to the time to reach peak, an increase in T R value results in a shift of the maximum response value to the right with a corresponding decrease in the peak response for simulations with the constraint and an increase for simulations without the constraint. The sharpness of the peak increases with increased T R . The models describe an effect of drug on the lifespan distribution of cells. This effect is concentration-dependent and consequently a temporal change in the lifespan distribution can be observed. appropriate correction for the sign. This implies that for strictly decreasing concentrations C(t), the response has a unique peak at time
pannel). Since for T D > T R , T R is equal
Consequently, the peak responses can be obtained from Eq. 17 by evaluating R(t peak ) = R peak
Equation 16 also implies the existence of a lag time for the response curve
Integration of both sides of Eq. 17 allows one to calculate the area between the baseline and the response curve, AUCE, as follows,
Equation 41 holds for any drug concentration for which the first moment is finite
The absolute value notation has been used to avoid differentiation between T D and T R . Derivations of the equations described above are shown in detail in Appendix A. In particular, for monoexponential drug concentrations, the integral in Eq. 41 can be calculated explicitly as follows:
For large doses, the responses will approach a limiting curve that can be characterized by explicit equations for dose-proportional concentrations and times t such that
Derivations of Eqs. 44 and 45 are presented in detail in Appendix B. Consequently, for large doses the slope of the onset part of the response curve is
, and the maximal response is defined as follows: To address estimability of the PD parameters 100 individual responses were simulated for model T D > T R with 10% constant coefficient of variation residual error. Next, the same model was fitted to such data and parameter estimates for successful minimizations were recorded. The histograms of their frequency distributions are shown in Fig. 8 . The number of successful minimizations was 68 out of 100. The ranges for parameter estimate distributions as well as the first, second, and third quartiles are presented in Table 1 . The true EC 50 value was 100 ng/ml. The ranges for E max estimates were 0.011-1 with the first (Q1), second (Q2), and third (Q3) quartiles 0.762, 1, and 1, respectively. If the quotient (T rue − Q2)/T rue × 100% is used as a relative measure of the bias of the parameter estimate, then biases for estimates of EC 50 , T D , T R , and R 0 were 1.6%, −25%, 6.7%, 1.7%, and 2.1%, respectively. Similarly, the ratio (Q3 − Q1)/T rue × 100% can be used as a measure of the precision of the parameter estimate. Then, the precisions for EC 50 , E max , T D , T R , and R 0 were 440%, 29.6%, 19.1%, 10.9%, and 7.9%, respectively. To determine if fixing E max improves bias and precision of the remaining parameters, the simulated data were re-fitted with E max = 0.8 (results not shown). The number of successful minimizations increased to 79. The biases for estimates of EC 50 , T D , T R , and R 0 were 8.5%, 7.7%, 2.9%, and 2.5%, respectively. The precisions were 295%, 15.1%, 12.9%, and 7.4%, respectively.
Model application
The estimates of parameters for the rHuEPO PK/PD model are shown in Table 2 . The Michaelis-Menten saturable elimination process was sufficient to describe the The number of successful minimization was 68. Q1, Q2, and Q3 denote first, second, and third quartiles, respectively disposition of rHuEPO as shown in Fig. 9 . Since our goal was to develop a relatively simple and minimalistic PK model that would adequately describe the rHuEPO serum concentrations the parameter estimates differ from their analogs from previously published models [4, 21] . The PK parameters were fixed and used to generate the rHuEPO serum concentration C that was the driving force for two pharmacodynamic effects: stimulation of the production of the progenitor cells (proliferation) and perturbation of the reticulocyte lifespan distribution. The mean reticulocyte data fitted by the PD model are shown in Fig. 10 . The estimate of the precursor cell lifespan in the bone marrow T C FU + T N O R was 5 days. This value is similar to the reticulocyte precursor lifespan reported previously [3] . The parameters k p and S max were not identifiable, and the estimate of the product k p · S max yielded the mean resident time for the BFU-E cells under the maximal erythropoietic stimulation of 16.9 days that is unphysiologically long, but consistent with analogous estimates published previously [5] . The value of the estimate for the rHuEPO potency parameter for the stimulatory effect on the proliferation was SC 50 = 16.3 IU/l, which is slightly higher than the baseline EPO levels and comparable with the values reported previously [4] . The objective of this case study was to assess the effect of rHuEPO on the reticulocyte lifespan distribution in the circulation. The estimate of the baseline reticulocyte lifespan T R was 1.7 days, which is the average time a homeostatic reticulocyte spends in the circulation. However, this value is in contrast with T R ET values obtained from the LIDR models previously used [4, 5] . Our study indicates that this discrepancy can be attributed to the assumption that rHuEPO in those models was not allowed to change the reticulocyte lifespan. The PK/PD model presented here predicts that rHuEPO might increase the RET lifespan in a dose-dependent manner by as much as 4.1 days. As presented in Fig. 11 , the mean reticulocyte lifespan M L R ET increases within T D = 4.1 days to the maximal value of T R + T D = 5.8 days. Then, it gradually returns to the baseline value, T R = 1.7 days, within 6 days for doses of 20 kIU and 9 days for doses of 160 kIU. The parameter EC 50 for this effect is estimated to be 73.2 IU/l, which implies that rHuEPO is about 4.5-fold less potent as an agent changing the reticulocyte lifespan distribution than as stimulator of the precursor production.
Discussion
The concept of the mean lifespan of a cell population as a delay time in the system variable has been used in various mathematical models of cell kinetics [22] . The idea of using a cell lifespan as a determinant of the removal rate was applied in the PK/PD area by Uherlinger et al. [23] . Its implementation in the context of indirect response models followed [3] . Subsequent applications of LIDR have been extended to modeling of toxic effects of anticancer agents, or effects of rHuEPO on erythropoiesis in humans and animals [4, [24] [25] [26] . These models were also applied to analyze data from patient populations [27, 28] . Another applications based on the convolution integral has been presented by Veng-Pedersen and collaborators [15, 29, 30] . Since the complex lifespan based PK/PD models require delay differential equations that are not supported by major PK/PD software packages, implementation of these concepts is faced with numerical challenges [20] . The transit or aging compartment PD models have been successfully used as an alternative approach to model delays in cell kinetics with-out numerical complexities associated with lifespan implementation [12, 13, 27, 31] . The drug effect on the mean lifespan of the cell population has been also adequately described by these type of models [12, 32] . Sensitivity analysis has revealed similarities between the LIDR model with T D > T R and IDR Model II as well as between the LIDR model with T D < T R and IDR Model IV [33] . All these models describe drug action on the response removal rate. A transient increase in the mean lifespan qualitatively results in a similar behavior of the response as a transient inhibition of the loss rate. Analogously, a transient decrease in the mean lifespan yields a response time course that is similar to the response to a stimulation of the loss rate. However, there are two distinct differences between these LIDR and IDR models. The presence of a lag time, and the independence of the time to peak response to dose for LIDR models are the main difference with the corresponding IDR models [33] . The latter property is also common to the basic LIDR models that describe stimulatory and inhibitory drug effects on the response production rate [3] . However, these two distinct features are consequences of the assumed simplistic lifespan distribution, which was centered at two points, T R and T D . In the case of continuous lifespan distributions that extend from 0 to infinity, the lag time in the response will be absent. Also, as shown previously for the basic LIDR models with continuous lifespan distributions, the time to peak response becomes dose dependent [14] .
Another conclusion that can be drawn from the exploratory analysis of the LIDR models is the high sensitivity of the response vs. time curve to all PD parameters, both system-related like T R , T D and R 0 , and drug-related like E max , and EC 50 . The parameters R 0 , T R , and T D can be clearly identified from the response at baseline, the lag time, and the time to maximum response. The drug-related parameters E max and EC 50 might require a relatively large dose to be resolved from single response data [34] . Also, since these parameters control the R vs. t curve in a similar manner, a higher correlation between their estimates might be expected, as observed for basic IDR models [34] . The simulations performed for model T D > T R with a dense sampling and 10% coefficient of variation of the residual error indicate that for a single dose response the estimates of EC 50 , T D , T R , and R 0 are not biased. The only biased parameter is E max with a distribution skewed to the right owing to an imposed upper limit of 1 on the parameter estimates. An acceptable precision of estimates was observed for parameters E max , T D , T R , and R 0 . The precision of EC 50 estimates was very low implicating that this parameter cannot be precisely estimated from single dose data.
The second least precise parameter was E max . Fixing E max to its true value did not improve the bias of parameter estimates and increased the precision, but the precision of EC 50 estimate remained very low. These findings are similar to estimability of the I max /S max and IC 50 /SC 50 parameters from single response data for the basic IDR models reported previously [34] . Further studies are necessary to address the question of estimability of these parameters from single dose data, optimal dosing designs, as well as optimal sampling time designs.
The partially integrated solutions of the presented LIDR models, the behavior of the responses for large doses, and the explicit equations for AUCE are similar to those presented previously for LIDR models, which described drug effects on the response production rate [3] . These relationships can be used to obtain initial values for the PD parameter estimates assuming large dose responses. In particular, the E max value can be obtained either from the maximal response or the initial slope. Resolving the EC 50 value from single dose response data is not straightforward and might involve a technique that uses AUCE that has been developed for the basic IDR models [35] . If additional experimental data regarding the mean lifespan dependence on time or concentration are available, one might apply Eq. 16 to determine EC 50 . The equation that relates AUCE and the area under the Hill function (Eq. 41) holds true not only for the LIDR models presented here, but also for the other type of LIDR models, as well as for basic IDR Models I and III. These universal characteristics serve as an additional argument for using AUCE as a measure of the net pharmacological effect for broadly understood indirect responses [36] .
The presented case study of the rHuEPO effect on reticulocyte lifespan in healthy subjects is meant to illustrate the implementation and the applicability of the LIDR models for drugs affecting cell lifespan distributions. The mean data were used for analysis. A limitation of the naïve pooled data analysis has been recognized previously [37] . However, for balanced study designs as in the example presented here, the naïve pooled data approach has been shown to provide unbiased estimates of model parameters [38] . Although the rHuEPO prolongation of the reticulocyte lifespan is well documented [14] , up to now this drug effect has been included only in few models used to describe the rHuEPO effects on reticulocytes [15] . Including such a process in the PK/PD model dramatically improves the estimate of the mean reticulocyte lifespan T R ET = 1.7 days that has been overestimated by LIDR models that only account for the stimulation of the production of the progenitor cells, T R ET = 3.1-6.7 days [3, 14] . A similar improvement can be expected for the estimates of the mean lifespan of RBC if such data are modeled by an analogous model. Such an effect of rHuEPO on the RBC lifespan distribution has been indicated by our previous study [14] .
A relatively high value of the estimate of K m = 3860 IU/l is consistent with the estimates of this parameter published previously and reflects moderate nonlinearity in rHuEPO disposition [4, 5] . A rHuEPO mechanism of action on survival of RBC is not currently known and might be difficult to determine in view of still not fully understood major processes that control RBC senescence and is further hampered by the duration of clinical studies [39] . Since the class of therapeutic proteins with the back bone structure identical to erythropoietin increases, it might be expected to observe similar effects of this class on the survival of RBC. Consequently, the model presented here could be applicable to analyze results of studies involving those agents. These types of models may be useful to explore the role of erythropoietin stimulating agents' half-life in the stimulation of the production rate of erythropoietic precursor cells and the prolongation of the reticulocytes' lifespan, which would be helpful to differentiate compounds that are already in the market (rHuEPO, darbepoietin, PEGrHuEPO). Also, it can be used in dealing with preclinical information and as the basis for the interspecies PK/PD extrapolation and the optimization of first in human studies as recently has been demonstrated using a similar mechanistic PK/PD model for rHuEPO [40, 41] . The examples of PEG-rHuMGDF and pegfilgastrim provide other potential applications of our concept to biologics affecting the thrombopoietic cell populations and neutrophils, respectively [12, 13] . Therefore, the current model is able to deal with drug effects that alter the lifespan distribution of cell populations and, as a consequence, it is useful to analyze the increase in lifespan of cells due to the entry of younger cells in the circulation, the inhibition of the apoptosis, and/or the prolongation of mature cell survival.
In summary, new LIDR models describing the pharmacological effects of agents that alter the lifespan distribution of cell populations have been developed. The properties of these models have been analyzed by computer simulations and methods of mathematical calculus. The new LIDR models exhibit similarities to the basic IDR Models II and IV both in the shape of the response curves and the way model parameters control the responses. However, the LIDR preserve distinct features like the presence of lag times and dose-independent time of peak response. Inclusion of the effect of rHuEPO on the reticulocyte lifespan distribution into a previously developed PD model resulted in an improved estimate of the mean reticulocyte lifespan. The concept presented here can be applied to other therapeutic agents that alter the lifespan distribution of cell populations. More in particular, they can be used to understand the changes in cell lifespan due to the entry of younger cells in the circulation, the inhibition or stimulation of apoptosis, and/or the modification of mature cell survival.
Derivation of Eq. 41
Consider the case T R < T D . Subtraction of R 0 from both sides of Eq. A2 and integration from 0 to t yields 
The l'Hospital rule and assumption imply that 
This completes the derivation of Eq. 44.
